Financials and Corporate

Cash, cash equivalents and financial assets* amounted to €176.6m (million euros) as of December 31, 2017 Revenue and other income amounted to €44.0m (€65.7m in 2016, including a €13.8m milestone...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that Prof. Jean-Yves Blay has been appointed to the Innate Pharma Supervisory Board. Prof. Blay brings significant...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that Professor Eric Vivier has joined the Company as Chief Scientific Officer (CSO) and Senior Vice President...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2018, which is set as follows: March 8, 2018: Publication of 2017 financial statements...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Cash, cash equivalents and financial assets amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma continues...

Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...